Sostoyanie uglevodnogo i lipidnogo obmena pri akromegalii

1. Балаболкин М.И. Диабетология. - М.: Медицина, 2000. - 672 с.

2. Балаболкин М.И. Эндокринология. - М.: Универсум паблишинг, 1998. - 584 с. 3. Болезни органов эндокринной системы: Руководство для врачей/ Дедов И.И.,

3. Балаболкин М.И., Марова Е.И. и др. Под ред. акад. РАМН И.И. Дедова. - М.: Медицина, 2000a. - 568с.

4. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению // Русский медицинский журнал. - 2001.- Т. 9.- № 2- С. 56-60.

5. Дедов И.И., Молитвословова Н.Н., Марова Е.И. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей. - Тверь: ООО «Издательство «Триада», 2003. - 40 с.

6. Долгов В., Морозова В., Марцишевская Р. и др. Клинико-диагностическое значение лабораторных показателей. - М.: «Лабинформ», «Центр». -1995.- 224 с.

7. Медведев В.В., Волчек Ю.З. Клиническая лабораторная диагностика: Справочник для врачей / Под ред. В.А. Яковлева. - СП-б.: Гиппократ, 1997. - 208 с.

8. Молитвословова Н.Н. Роль соматотропина и гормонов поджелудочной железы в генезе нарушений углеводного обмена при акромегалии: Дис. канд. мед. наук. - М., 1983.

9. Перова Н.В. Место диагностики атерогенных дислипопротеидемий в профилактике сердечно-сосудистых заболеваний // Сердце. - 2002. - Т. 1. - № 3 - С. 126 - 127.

10. Abbasi F., Brown B.W.Jr., Lamendola C. et al. Relationship between obesity, insulin resistance, and coronary heart disease risk // J. Am. Coll. Cardiol. - 2002. - Vol. 40, №5. - P. 937-943.

11. Akazawa S., Yamasaki H., Yamaguchi Y., Nagataki S. Atherosclerosis and endocrine disorders // Nippon. Rinsho. - 1993. - Vol. 51, №8. - P. 2190-2194.

12. Arosio M., Sartore G., Rossi C. et al. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group // Atherosclerosis. - 2000. - Vol. 151, № 2. - Р. 551-557.

13. Ayuk J., Stewart S.E., Stewart P.M., Sheppard M.C. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87, №9. - P. 4142-4146.

14. Beentjes J., van Tol A., Sluiter W. Dullaart R. Low plasma lecithin:cholesterol acyl- transferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins // Atherosclerosis. - 2000. - Vol. 153, № 2. - Р. 491-498.

15. Beentjes J., van Tol A., Sluiter W. Dullaart R. Low plasma lecithin:cholesterol acyl- transferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins // Atherosclerosis. - 2000. - Vol. 153, № 2. - Р. 491-498.

16. Biering H., Knappe G., Gerl H., Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome // Acta Med. Austriaca. - 2000. - Vol. 27, №1. - P. 27-31.

17. Capiello V., Ronchi C., Morpurgo P.S. et al. Circulating ghrelin levels in basal con- ditions and during glucose tolerance test in acromegalic patients // Eur. J. Endocrinol. - 2002. - Vol. 147, № 2. - P. 189-194.

18. Colao A., Baldelli R., Marzullo P. et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomy- opathy // J. Clin. Endocrinol. Metab. - 2000a. - Vol. 85, № 1. - Р. 193-199.

19. Colao A., Spiezia S., Cerbone G. et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly // Clin. Endocrinol. (Oxf). - 2001c. - Vol. 54, № 4. - Р. 515-524.

20. Ezzat S., Forster M., Berchtold P. et al. Clinical and biochemical features in 500 patients // Medicine (Baltimore). - 1994. - Vol. 73, № 5. - Р. 233-240.

21. Fukuda I., Hizuka N., Murakami Y. et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University // Intern. Med. - 2001. - Vol. 40, №10. - P. 987-992.

22. Gama R., Teale J.D., Wright J. et al. Hyperproinsulinaemia in acromegaly: evidence for abnormal pancreatic beta-cell function? // Ann. Clin. Biochem. - 1997. - Vol. 34, № 6. - P. 627-631.

23. Haban P., Simoncic R., Zidekova E., Ozdin L. Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome // Med. Sci. Monit. - 2002. - Vol. 8, №3. - CR. 175-179.

24. Harris A. Acromegaly and its management. - Philadelphia, USA: Lippincott Raven Publishers, 1996. - P. 175.

25. Jaffrain-Rea M., Moroni C., Baldelli R. et al. Relationship between blood pressure and glucose tolerance in acromegaly // Clin. Endocrinol. (Oxf). - 2001. - Vol. 54, № 2. - Р.189-195.

26. Kasayama S., Otsuki M., Takagi M. et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients // Clin. Endocrinol. (Oxf). - 2000. - Vol. 52, № 5. - Р. 549-555.

27. Kreze A., Kreze-Spirova E., Mikulecky M. Risk factors for glucose intolerance in active acromegaly // Braz. J. Med. Biol. Res.- 2001. - Vol. 34, №11. - P. 1429-1433.

28. Landin-Wilhelmsen K., Tengborn L., Wilhelmsen L., Bengtsson B. Elevated fibrino- gen levels decrease following treatment of acromegaly // Clin. Endocrinol. (Oxf). - 1997. - Vol. 46, №1. - P. 69-74.

29. Maldonado G., Escobar-Morreale H., Ortega H. et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly // Clin. Endocrinol. (Oxf). - 2000. - Vol. 53, № 3. - Р. 313-319.

30. Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. - 1985. - Vol. 28, №7. - P. 412-419.

31. Otsuki M., Kasayama S., Yamamoto H. et al. Characterization of premature athero- sclerosis of carotid arteries in acromegalic patients // Clin. Endocrinol. (Oxf). - 2001. - Vol. 54, № 6. - Р. 791-796.

32. Piniewska-Hulas D., Lewandowski Z., Kasperska-Dworak A., Bonicki W. Relationship between fasting glycemia, serum peptide C, insulin, growth hormone and plasma glucagon in acromegaly // Pol. Arch. Med. Wewn. - 1996. - Vol.95, № 6. - P. 524-533.

33. Reaven G. Insulin resistance, hypertension, and coronary heart disease. // J. Clin. Hypertens. (Greenwich). - 2003. - Vol. 5, №4. - P. 269-74.

34. Rose D., Clemmons D. Growth hormone receptor antagonist improves insulin resist- ance in acromegaly // Growth Horm. IGF Res. - 2002. - Vol. 12, № 6. - Р. 418-424.

35. Silha J.V., Krsek M., Hana V. et al. Pertubations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance // Clin. Endocrinol. (Oxf). - 2003. - Vol. 58, № 6. - P. 736-742.

36. Tan K., Shiu S., Janus E., Lam K. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I // Atherosclerosis. - 1997. - Vol. 129, № 1. - Р. 59-65.

37. Tsai J., Zorrilla L., Jacob K. et al. Nocturnal monitoring of growth hormone, insulin, C-peptide, and glucose in patients with acromegaly // Am. J. Med. Sci. - 1996. - Vol. 311, №6. - Р. 281-285.

38. Tsuchiya H., Onishi T., Mogami H., Iida M. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy // Endocrinol. Jpn. - 1990. - Vol. 37, №6. - P. 797-807.

39. Twickler T., Dallinga-Thie G., Zelissen P. et al. The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients // Clin. Endocrinol. (Oxf). - 2001. - Vol. 55, №1. P. 69-75.